Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: Does it make sense?

American Journal of Therapeutics

Volumn 12, Issue 4, 2005, Pages 320-327

  El Desoky, Ehab S ^a   Madabushi, Rajanikanth ^b   Amry, Salah El Din A ^a   Bhattaram, Venkatesh Atul ^c   Derendorf, Hartmut ^b  

^a Assiut University Faculty of Medicine   (Egypt)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Digoxin; Pediatrics; Population pharmacokinetics; Serum creatinine

Indexed keywords

CREATININE; DIGOXIN;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG CONCENTRATION; EGYPT; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEART FAILURE; HUMAN; INFANT; MAINTENANCE DRUG DOSE; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; VALIDATION PROCESS;

ADOLESCENT; CARDIOTONIC AGENTS; CHILD; CHILD, PRESCHOOL; CREATININE; DIGOXIN; DRUG MONITORING; EGYPT; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEART FAILURE, CONGESTIVE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE;

EID: 25844513121     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000155108.62208.82     Document Type: Article

References (22)

1. Goodman A, Goodman LS, Rall TW, eds. The Pharmacological Basis of Therapeutics, 7th ed. New York: Macmillan; 1985:716.
2. Yusuf S. Clinical experience in protecting the failing heart. Clin Cardiol. 1993;16(5 suppl 2):II 25-29.
3. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
4. Wettrell G, Andersson KE. Cardiovascular drugs. II: Digoxin. Ther Drug Monit. 1986;8:129-139.
5. EL Desoky ES, Nagaraja NV, Derendorf H. Population pharmacokinetics of digoxin in Egyptian pediatric patients: impact of one data point utilization. Am J Ther. 2002;9:492-498.
6. Bendayan R, McKenzie MW. Digoxin pharmacokinetics and dosage requirements in pediatric patients. Clin Pharmacokinet. 1983;2:224-235.
7. Steinberg C, Notterman DA. Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors. Clin Pharmacokinet. 1994;27:345-367.
8. Park MK. Use of digoxin in infants and children, with specific emphasis on dosage. J Pediatr. 1986;108:871-877.
9. Latifi S, Lidsky K, Blumer JL. Pharmacology of inotropic agents in infants and children. Prog Pediatr Cardiol. 2000;12:57-79.
10. Suematsu F, Minemoto M, Yukawa E, et al. Population analysis for the optimization of digoxin treatment in Japanese pediatric patients. J Clin Pharm Ther. 1999;24:203-208.
11. Breant V, Charpiat B, Sab JM, et al. How many patients and blood levels are necessary for population pharmacokinetic analysis. A study of a one-compartment model applied to cyclosporine. Eur J Clin Pharmacol. 1996;51:283-288.
12. Schwartz GJ, Gauthier A. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985;106:522-526.
13. Shapiro W, Narahara K, Taubert K. Relationship of plasma digitoxin and digoxin to cardiac response following intravenous digitalization in man. Circulation. 1970;42:1065-1072.
14. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit. 2000;22:137-140.
15. Jonsson EN, Karlsson MO. Xposean S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
16. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic models. In: D'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic System Analysis. New York: Plenum Press; 1995:69.
17. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59:19-29.
18. Hastreiter AR, van der Horst RL, Voda C, et al. Maintenance digoxin dosage and steady-state plasma concentration in infants and children. J Pediatr. 1985;107:140-146.
19. Suematsu F, Yukawa E, Yukawa M, et al. Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. Eur J Clin Pharmacol. 2001;57:19-24.
20. Martin-Suarez A, Falcao AC, Outeda M, et al. Population pharmacokinetics of digoxin in pediatric patients. Ther Drug Monit. 2002;24:742-745.
21. Wettrell G, Andersson KE. Clinical pharmacokinetics of digoxin in infants. Clin Pharmacokinet. 1977;2:17-31.
22. Linday LA. Developmental changes in renal tubular function. J Adolesc Health. 1994;15:648-653.